“It’s no wonder that Big Pharma is looking to emerging markets to lift sales. These fast-growing countries are about the only areas where drug spending will increase significantly. The global drug market may be aiming for $1.2 trillion by 2016, but 16 “pharmerging” countries will take a much bigger bite of that total.
…Consider India. Its drug spending is mushrooming as the government boosts healthcare investment, the middle class grows, and chronic diseases like diabetes become more prevalent.”
Or China, arguably the fastest-growing drug market in the world. The government has pledged billions toward building up a better healthcare system.
Which brings us to another consequence of the West’s falling share of drug spending. As international drugmakers focus their attention away from U.S. and Europe, their operations at home could continue to shrink. Already, companies such as Eli Lilly ($LLY) and Sanofi ($SNY) have slashed their sales forces in U.S and Europe while hiring by the hundreds in China.
US slashing sales force – will that mean lower drug prices for citizens?
Will these drug manufacturers push more of their efforts into the mental health community especially where unknown drug therapy for dissociative identity disorder, for example, have yet to be proven?
There is already a push to put kids on pharmaceuticals at younger and younger ages. It can only continue until the damage is epidemic.